The technique of lymphatic mapping and sentinel lymph node (SLN) biopsy for melanoma has emerged during the last 2 decades as a minimally invasive approach to evaluate regional lymph node basins in patients with intermediate-and high-risk primary cutaneous melanoma and has changed our approach to the clinically negative lymph node basin in melanoma during the same period. This review focuses on preoperative assessment and operative strategies, pathologic evaluation of the SLN, issues related to regional lymph node basin control, and current clinical practice guidelines. Predictors of SLN status, the prognostic significance of the SLN, and areas of controversy are also discussed. FIGURE 1. Sentinel lymph node technique and localization. A, After intradermal injection of blue dye at the site of the primary cutaneous melanoma of the left abdominal wall, afferent lymphatics drain to the left inguinal lymph node and 2 left axillary lymph nodes. B, The first of 2 SLNs is visualized in the left axilla. From Gershenwald and Ross 1 with permission.
T he technique of lymphatic mapping and sentinel lymph node (SLN) biopsy for melanoma has emerged during the last 2 decades as a minimally invasive approach to evaluate regional lymph node basins in patients with intermediate-and high-risk primary cutaneous melanoma. Goals of SLN biopsy include accurate nodal staging, identification of patients with clinically occult, microscopic lymph node disease who may benefit from further treatment, regional nodal control, and a possible survival benefit. 1Y3 Moreover, this approach may also identify a subset of patients for whom further treatment is not indicated, sparing them from unnecessary surgical procedures or systemic therapies. 1, 3 In this review, we examine the evolution of SLN biopsy as a technique, the preoperative assessment and operative strategy, the pathologic evaluation of the SLN, the current practice guidelines, the prognostic significance of SLN biopsy findings, and the potential complications of the procedure and address some of the current areas of controversies in the field.
BACKGROUND AND RATIONALE
Historically, the approach to regional lymph nodes in patients with intermediate-or high-risk primary cutaneous melanoma was (1) formal elective lymph node dissection (ELND) at the time of initial surgical treatment of the primary melanoma or (2) nodal observation followed by therapeutic lymph node dissection (TLND) if clinically evident regional lymph node disease developed. Proponents of aggressive treatment of early disease via ELND suggested that removal of microscopically involved regional lymph nodes would prevent the development of clinically detectable lymph node disease, as well as eliminate a potential source of distant failure. However, the contrary argument for nodal observation focused on the lack of benefit in ELND for most patients, while having an associated cost and morbidity of an unnecessary operation. 3 Both of these approaches had obvious disadvantages including difficulty with longterm control in patients for whom TLND was done for clinically palpable disease (recurrence rates of 50%) 4,5 versus surgical morbidity in the setting of clinically negative lymph node status. 4, 5 To address these issues, several prospective randomized studies were undertaken to compare TLND to ELND. 6Y9 In the 1970s and 1980s, the World Health Organization (WHO) Melanoma Group and the Mayo Clinic each conducted clinical trials to assess whether ELND may be associated with a survival benefit; overall, neither of these early trials showed improved survival in patients undergoing ELND. 8, 9 Subsequently, the Intergroup Trial and another WHO study examined this same theme in a population of higher risk, clinically nodenegative patients. In these later studies, there were trends for improved survival with ELND, although they did not reach statistical significance. 6, 7 Analysis of patients in the WHO Trial demonstrated decreased survival in patients who developed clinical adenopathy after nodal observation compared to those who underwent ELND and had microscopic disease, 7 suggesting that the treatment of regional node disease while still microscopic affords a survival benefit compared to waiting for the development of clinically evident disease. In the Intergroup study, subgroup analysis demonstrated that patients with melanomas between 1 and 2 mm thick and all patients with nonulcerated primaries had improved survival with ELND. 6 Nonetheless, because no overall survival difference was observed in these studies, yet all patients offered such a procedure would be at risk for complications and morbidity associated with lymphadenectomy, this approach fell out of favor. 6Y9 Subsequent criticism of these studies has noted that these studies were not sufficiently powered to address the endpoint of overall survival given the small proportion of patients (15%Y20%) who could actually benefit from lymphadenectomy (ie, patients who actually have lymph node metastasis) in these studies.
The ''science'' behind the concept of lymphatic mapping and SLN biopsy is based on the premise that different regions of the skin have specific patterns of lymphatic drainage and that the SLN(s) is(are) the first site(s) of regional lymphatic drainage ( Fig. 1 ). As such, the histology of the SLN is representative of the histology of the entire nodal basin. 10Y13 This approach derives from the theory that metastases from melanoma most commonly develop first in the regional lymph node basins and then subsequently move to distant metastatic sites. 10 The goal of identifying clinically occult microscopic metastatic disease in this context is to prevent the presumed progression to clinically detectable nodal disease. 14 The SLN biopsy concept for melanoma was first proposed in the 1980s, 12, 15 and the original studies by Morton et al 15 established SLN identification rates of approximately 82% using blue dye alone and false-negative rates of 5% based on concomitant ELND at the time of SLN biopsy. Further studies by other institutions, including The University of Texas MD Anderson Cancer Center, the Sydney Melanoma Unit (currently known as Melanoma Institute Australia), and Moffitt Cancer Center corroborated these early observations. 11Y13, 16 As a technique, SLN biopsy offered more accurate staging than clinical examination alone with less morbidity than ELND. In subsequent studies, the rates of in-basin recurrence after a negative SLN biopsy were 2% to 10%, 17 compared with 20% to 50% in the regional nodal basin after TLND for palpable disease. 4, 5 Preoperative Assessment and Operative Strategy
The preoperative workup for patients offered lymphatic mapping and SLN biopsy includes a physical examination; preoperative lymphoscintigraphy 18 (Fig. 2 ) or single-photon emission computed tomography (SPECT)YCT 19 is generally also performed, depending on the location of the primary melanoma. 20 The goal of lymphoscintigraphy is to establish an individualized preoperative ''road map'' of nodal basin drainage that will guide intraoperative identification of SLNs. 1, 18 Such an approach is particularly important for melanomas of the trunk and head and neck, all of which may drain to multiple node basins ( Fig. 2 ). The addition of SPECT-CT to routine lymphoscintigraphy has become increasingly common, particularly for the evaluation of head and neck melanomas, 19 as it offers enhanced anatomicospatial localization of the SLNs. Preoperative ultrasound has also been used to evaluate of lymph node basins that are equivocal or suspicious on physical examination; fine needle aspiration is generally performed if the ultrasound findings are suspicious. In theory, ultrasound can be used both preoperatively for screening and postoperatively for follow-up of the lymph node basins, with variability in the sensitivities reported in several studies ranging from 24% to more than 80%. 20Y26 Overall, the role of ultrasound as an adjunct to SLN biopsy is not completely resolved. 23 Routine use of a screening chest radiograph is generally not recommended unless there are localizing symptoms, 27 although an initial study may be used as a baseline.
The addition of radiocolloid with intraoperative use of the gamma probe, in addition to isosulfan blue (ie, a dual modality approach), has been shown to increase the rate of SLN identification to more than 99% 28 at the time of the SLN biopsy procedure and currently represents a standard approach adopted by most surgeons (Fig. 3 ). 29 In addition to named major regional lymph node basins (eg, cervical, axillary, inguinal), the SLN biopsy technique may identify SLNs outside these formal basins approximately 5% to 10% of the time, with similar rates of microscopic disease as in the major regional lymph node basins. 30 Such SLNs are called unusual, in-transit, or ectopic SLNs. 30Y33 Lymphatic drainage to epitrochlear and popliteal regions (so-called minor basins) are also observed. 18, 30 Because the histological status of SLNs within different basins in an individual patient may be discordant, 34 it is essential that all potential drainage basins from each melanoma site be thoroughly assessed to achieve accurate nodal staging. From a technical standpoint, it is recommended that whenever possible, SLN biopsy be performed before wide excision of the primary melanoma to minimize disruption of lymphatic vessels at the time of the SLN biopsy procedure. 35 
Pathologic Evaluation of the SLN
The pathologic evaluation of the SLN is of utmost importance. Historically, before the advent of SLN biopsy, excised lymph nodes were bivalved, and representative sections were assessed by hematoxylin and eosin staining for the presence of metastatic melanoma tumor deposits. More recently, step sectioning has been used, and it is associated with improved detection of microscopic disease. 17, 36 Immunohistochemical evaluation has been widely embraced as a complement to conventional hematoxylin and eosin staining, and it enhances detection of microscopic SLN metastases. 29 Intraoperative frozen-section analysis is generally not recommended because of the reduced sensitivity of this technique, 37 although this approach may be used if a grossly suspicious SLN is observed and preoperative discussion regarding concomitant lymphadenectomy has already occurred. 37, 38 Interestingly, in a retrospective study of 270 patients at MD Anderson who had histologically negative SLN biopsy between 1991 and 1995 (ie, before routine use of step sectioning and/or immunohistochemical analysis of SLNs), 14 patients (11%) developed local, in-transit, regional nodal, and/or distant metastases after a median follow-up of 35 months. Of these 14 patients, 10 (4.1% overall) developed a regional nodal recurrence in previously mapped basins as a first site of failure. Eight (80%) of these 10 patients were found to have evidence of occult metastases in their SLN on enhanced examination of the original blocks by serial sectioning and/or immunohistochemistry, 17 suggesting that false-negative results may be due to inadequate sampling and assessment rather than identification of a non-SLN or other source of technical failure. These false-negative rates have likely decreased, as these forms of enhanced histological evaluation of the SLN have become routine.
Regional Node Basin Control
Another area of interest is whether there is improvement in regional disease control with completion lymph node dissection (CLND) for microscopic disease. Historically, the most common site of recurrence after wide excision alone was the regional lymph node basin. In the setting of TLND for clinically palpable disease, there is a failure rate in the lymph node basin of 9% to 50%. 4, 5, 39, 40 This rate depends on a number of factors, including the basin site (ie, neck, axilla, or groin), the number of involved nodes, lymph node tumor burden, and the presence of extracapsular extension. 40Y42 In addition to the oncologic significance of these recurrences, they are also associated with significant morbidity and pain. However, in the setting of SLN biopsy, the in-basin failure rates is less than 10% after CLND for patients with microscopic disease, 15, 43 suggesting that early treatment of regional lymph node metastasis does promote regional control.
Current Practice Guidelines
The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Melanoma recommend that SLN biopsy be discussed with and offered to patients with stage IB and stage II melanoma. Although there are no uniformly accepted guidelines for stage IA melanoma, the NCCN guidelines suggest that SLN biopsy should be considered 35 Although there is a theoretical risk of lymphatic disruption of afferent lymphatic vessels and alteration of lymphatic drainage patterns after wide excision, existing data support that SLN biopsy after wide excision accurately reflects regional lymph node status in most patients. 35 The role of SLN biopsy in patients with thick melanomas (94 mm) has been questioned by some because, compared to patients with thinner tumors, these patients are at an increased risk of distant metastatic disease. However, several studies have demonstrated that, even among patients with thick melanomas, SLN status is still the most important predictor of survival. 43, 54, 55 
Predictors of SLN Status and Prognostic Significance of the SLN
Multiple predictors of SLN metastasis have been reported, including tumor thickness and ulceration, 47, 50 as well as high mitotic rate and LVI. 46, 48, 49, 51, 56 Several studies have also examined the prognostic significance of SLN status. 5, 6, 57, 58 Survival analyses of stage I and stage II melanoma patients have demonstrated that the histologic status of the SLN is the most powerful independent predictor of survival in clinically nodenegative patients 57, 59, 60 ; other clinicopathologic factors are also important predictors of survival. 4, 10 The 5-year survival rate among all patients with a negative SLN biopsy in the Multicenter Selective Lymphadenectomy Trial-1 (see below) is 90%, 5 supporting that additional factors contribute to survival in addition to SLN status. Stratification of these overall ''low-risk'' patients into additional risk categories to guide subsequent surveillance and treatment remains an important goal. Among patients with a negative SLN, there is an approximately 3% to 5% recurrence rate in the mapped regional nodal basin, 11Y13,15 and this may be related to misidentification of the ''true'' SLN, microscopic in-transit metastasis outside the lymph node basin, or inadequate lymph node sampling during pathologic assessment.
One of the most important clinical trials to date in the SLN arena is the Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1), which randomly assigned 1269 patients with primary melanoma of 1 mm or greater to (1) SLN biopsy with CLND for a positive SLN or (2) nodal observation and TLND for palpable nodal disease. 5 The primary endpoint was melanomaspecific survival, with secondary endpoints of disease-free survival and melanoma-specific survival, stratified according to SLN status. At the third interim analysis, 5 there was no significant difference in melanoma-specific survival at 5 years (the primary endpoint of this study), with a survival rate of 86.6% for the observation group and 87.1% for the SLN biopsy group (hazard ratio, 0.92; 95% confidence interval, 0.67Y1.25). 5 In a prespecified analysis, however, patients in the observation group in whom clinical nodal disease developed and underwent TLND had a significantly poorer melanoma-specific survival at 5 years (52.4%) compared with the positive SLN biopsy group who underwent immediate CLND (72.3%) (hazard ratio, 0.51; 95% CI, 0.32Y0.81; P = 0.007). 5 The validity of these assumptions is based on the premise that all micrometastases in the SLN will progress to palpable disease if left untreated, 1 and this underscores the importance of treatment of microscopic rather than macroscopic disease. Published reports (in 2010) from the fourth interim analysis of this trial examined the morbidity associated with early versus late CLND and found increased surgical morbidity, particularly lymphedema, in patients undergoing late CLND. 61 The final analysis of these data has not yet been published.
Complications
Although well tolerated by most patients, the SLN biopsy procedure is not without risk of complications. The technique has been associated with wound infection, seroma, and hematoma; regional complications such as lymphedema, pain, numbness, and decreased range of motion have also been described. Despite these risks, the incidence of these complications is significantly less than for patients who undergo TLND. In the MSLT-1 trial, the overall surgical site complication rate was 10% for SLN biopsy compared with 37% in those patients who had CLND for a positive SLN. 62 Moreover, patients with a positive SLN who underwent CLND had a lower incidence of lymphedema and shorter hospital stay compared with those who underwent a TLND in the context of clinically palpable lymph nodes manifesting in a delayed fashion after wide excision alone. 61 In the Sunbelt Melanoma Trial, the overall complication rate among patients who underwent SLN biopsy was 4.6% versus 23.2% for those who had a positive SLN biopsy and subsequently underwent CLND. The most notable complications were wound infection (1.1% vs 7%), lymphedema (0.7% vs 11.7%), and hematoma/seroma (2.3% vs 5.9%). 63 There have also been allergic reactions to the blue dye reported, although the incidence is quite low (0.2% in MSLT-1). 15, 62 
Areas of Controversy

Survival Benefit
Despite widespread adoption of SLN biopsy, there exist areas of ongoing debate. One such issue is whether SLN biopsy and ''early'' CLND improves survival. The summarized experience of the early ELND studies demonstrated that there was no overall survival benefit to ELND, recognizing again the criticism that the number of node-positive patients was too low to adequately test this hypothesis. However, in view of subset analyses supporting improved survival specifically among the nodepositive patients, as well as the development of the SLN biopsy technique, the question surrounding the benefit of early regional node control was applied to SLN biopsy studies. In the MSLT-1 trial, there was a small, but statistically significant increase in 5-year disease-free survival in patients who underwent SLN biopsy (78.3% T 1.6%) compared to those who were followed with nodal observation after wide excision alone (73.1% T 2.1%; HR, 0.74; 95% CI, 0.59Y0.93; P = 0.009). 6 More pronounced was the difference in 5-year melanoma-specific survival seen in patients who underwent delayed lymph node dissection for clinical nodal failure (52.4% T 5.9%) versus those who underwent early TLND after a positive SLN (72.3% T 4.6%; HR for death, 0.51; 95% CI, 0.32Y0.81; P = 0.004), 6 supporting the concept of survival benefit when treating microscopic rather than macroscopic disease. In 2006, the third interim analysis of the MSLT-1 trial demonstrated that a positive SLN was the most important prognostic factor in assessing outcomes. 5, 62 Increased risk of in-transit metastases? The concept of a theoretical increased risk in in-transit metastases (ITM) has been raised with SLN biopsy given the alterations in lymphatic flow and potential lymphatic obstruction; however, there are no data to support this contention. 64Y66 Instead, evidence from singleinstitution 64, 65 and randomized clinical trials alike 5 strongly support that tumor biologyVand not surgical approachVis the most important predictor of ITM. Indeed, predictors of ITM include older age, lower extremity primary, thicker primary tumors, ulceration, and positive, SLN biopsy status. 64, 66 Importantly, the risk of ITM does not seem to be related to whether an SLN biopsy was performed at the time of wide excision. 64, 66 
Role of Completion Lymphadenectomy
Because only 8% to 25% of patients with a positive SLN biopsy will have additional microscopic disease at the time of TLND, 67 the question remains as to whether there is a subset of patients with microscopic lymph node metastasis for whom a CLND may not be necessary. An obvious issue in assessment of the CLND specimen is the sheer volume of tissue to be evaluated. As mentioned above (see section on SLN pathology), improvements in the detection rate have been associated with step sectioning, a technique that is essentially impractical to apply to large-volume patient samples such as lymphadenectomy specimens; therefore, a large sample size is also associated with an increased risk of overlooking disease from a purely technical standpoint.
Given the low overall incidence of non-SLN involvement at the time of CLND, several studies have focused on identifying predictors of non-SLN involvement. Some of the factors identified thus far include SLN tumor burden, number of SLNs harvested, and primary tumor thickness. 67Y73 To address the question regarding the need for CLND for patients with a positive SLN, the MSLT-2 trial was designed and is currently accruing patients. It is a prospective, randomized trial comparing TLND to nodal basin observation and surveillance with ultrasound in patients with a positive SLN biopsy. The primary outcome being measured is melanoma-specific survival; secondary outcomes include disease-free survival and recurrence. The goal of this study was to address the survival impact, if any, of a CLND by comparing CLND to observation. The secondary outcomes will address the incidence of nodal failure after removal of a positive SLN in the absence of a CLND. The hope is that this trial will also shed some light on the incidence and predictors of additional positive non-SLN in the mapped basin. The plan is for a 10-year follow-up of these patients.
In Europe, this issue is also being explored with the MINITUB study, a prospective, single-arm registry study evaluating the efficacy of not performing CLND on patients with minimal tumor burden (G0.1 mm) in their positive SLN. The planned follow-up of this study is also 10 years, with a primary endpoint of distant metastasis-free survival and secondary endpoints examining the rate of TLND for clinical nodal disease relapse and long-term lymph node basin control rates. The overall goal is to assess the effects of omission of CLND on patients considered to have a low burden of regional lymph node disease.
Future Directions
It is unquestionable that nodal assessment via SLN biopsy has changed the management of regional lymph nodes in melanoma. Work is ongoing to establish which subsets of patients require more aggressive treatment as well as those for whom a less aggressive strategy is warranted. Advances in imaging and pathologic assessment will also play a large role in our identification and management of melanoma in the near future. As our ability to molecularly assess these tumors improves, genomics and proteomics will allow us to complement conventional clinicopathological factor assessment and further enhance our ability to stratify patients according to the biology of their disease. This approach has the additional potential benefit of informing rational and contemporary treatment regimens, if ''at-risk,'' based on underlying molecular aberrations of the tumor and according to a patient's predicted risk of locoregional and/or distant disease and potential likelihood of response. Moreover, patients considered to be at very low risk based on multifactorial assessment may be spared additional treatment and perhaps be offered less intensive follow-up than might otherwise be recommended.
